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Abstract
BACKGROUND: Abdominal pain is a common complaint in children and its differential diagnosis includes inflammatory bowel 
disease (IBD). The aim of the study was to assess the diagnostic accuracy of scintigraphy with 99mTechnetium Hexamethylpro-
pyleneamine Oxime (99mTc-HMPAO) labeled leukocytes in children with suspected IBD.
MATERIAL AND METHODS: Eighty-five children (age 12.4 ± 4.3 years, 47% boys) with suspected IBD based on clinical 
presentation, laboratory and ultrasound findings underwent scintigraphy with 99mTc-HMPAO labeled leukocytes. Abdominal 
scintigrams were acquired 40 min and 90 min post injection, and whole body scintigrams at 180 min. Scintigraphy was evalu-
ated by two specialists in nuclear medicine. The results were compared with the final diagnosis established by endoscopy, 
histology, other imaging methods, and follow-up evaluated by an expert in pediatric gastroenterology.
RESULTS: Scintigraphy results corresponded with the final diagnosis in 78 (91%) patients resulting in a sensitivity of 89% (95% 
CI 72 to 98%), specificity of 91% (95% CI 82 to 98%), and accuracy of 91% (95% CI 83 to 96%). The interobserver agreement 
was 0.82 (95% CI 0.75 to 0.88) and the radiation dose estimate was 4.2 ± 1.5 mSv. In 28 children (25 positives and 3 nega-
tives on scintigraphy), the diagnosis of IBD was established by endoscopy, histology, MR enterography, or fluoroscopy. Five 
positive findings on scintigraphy were not confirmed by other methods or during follow-up. 
CONCLUSION: Scintigraphy with 99mTc-HMPAO labeled leukocytes in children with suspected IBD has high accuracy and of-
fers a non-invasive option for detecting the presence of gastrointestinal inflammation. Scintigraphy is a powerful non-invasive 
decision-making tool in the management of suspected IBD that may spare a greater proportion of children of more invasive 
and demanding examinations.
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Introduction
Abdominal pain is one of the most common complaints in 
children [1]. In up to 95% of these children, no underlying cause 
can be detected, but is essential to identify the remaining 5% with 
organic pain [2–4]. Although the differential diagnosis is very broad 
and varies with age, the possibility of inflammatory bowel disease 
(IBD) should be considered. The incident rate of IBD is increasing 
and its first clinical presentation can be traced to an even younger 
age [5]. IBD etiology remains obscure. A coincidence of genetic 
predispositions, environmental factors and changes in the gut mi-
crobiome is suspected [6]. IBD encompasses the Crohn’s disease 
(CD), ulcerative colitis (UC) and IBD unclassified (IBDU) [7]. CD is the 
most frequent type of IBD in children with a prevalence of 58 per 
100 000 children [8, 9]. CD can affect any part of the gastrointestinal 
(GI) tract from the mouth to anus, most commonly ileum and colon.
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The diagnosis of IBD is based on clinical presentation, labo-
ratory tests, endoscopic findings, histology, and imaging [7, 10, 
11]. Abdominal ultrasound is the first-line imaging modality, but GI 
scintigraphy can be useful in the early phase of investigation as well 
[12]. GI scintigraphy with 99mTechnetium Hexamethylpropyleneam-
ine Oxime (99mTc-HMPAO) labeled leukocytes evaluates the loca-
tion and the severity of the suspected inflammation and has been 
used in this indication for over 20 years. It has a high sensitivity 
for detecting IBD with a high negative predictive value but the 
awareness about its usefulness is waning [11, 13, 14]. Finding of 
inflammatory activity in the bowel on scintigraphy would warrant 
more invasive examinations as colonoscopy. Although MR enter-
ography (MRE) is considered the imaging modality of choice (after 
first-line ultrasound) due to excellent visualization of the small bowel, 
satisfactory depiction of large bowel, and the absence of radiation 
burden, it requires good cooperation of the child, who has to drink 
a considerable amount of contrast material and hold breath when 
asked. Motion artifacts and poor bowel distension may render MR 
enterography non-diagnostic in some cases [15].
The goal of this study was to evaluate the diagnostic perfor-
mance of scintigraphy with 99mTc-HMPAO labeled leukocytes in the 
detection of IBD in children and to revisit the role of scintigraphy in 
the diagnostic workflow of children with suspected IBD. 
Patients and methods
This retrospective study was performed in accordance with the 
Declaration of Helsinki, it was approved by the local Ethics Com-
mittee, and informed consent was waived.
Altogether 85 consecutive children between 4 and 18 
years (12.4 ± 4.3 years, 47% boys) with abdominal complaints, who 
were examined by 99mTc-HMPAO labeled leukocytes GIT scintigra-
phy between January 2010 and March 2018, were enrolled in the 
study. The examination was requested after detailed physical and 
laboratory examinations, and abdominal ultrasound for diagnostic 
uncertainty that could suggest IBD.
The children were examined fasting. A total of 0.5–1 ml of blood 
per kg of body weight (average weight 44 ± 17 kg) was sampled 
into sterile syringes with aliquot amounts of anticoagulant citrate 
dextrose solution and 6% hydroxyethyl starch. The leukocyte 
separation and their labeling was performed according to the 
manufacturer’s manual with the following steps: 1) spontane-
ous sedimentation of erythrocytes, 2) supernatant centrifugation, 
3) separation of leukocytes, and 4) their labeling with 99mTc-HMPAO 
in an amount based on the child’s weight followed by 5) incubation 
at room temperature, 6) centrifugation for acquiring blood plasma 
and 7) removal of free 99mTc-HMPAO. A suspension of labeled 
leukocytes with an activity of 175–700 MBq was then ready to be 
re-injected into the systemic circulation. The administered amount 
of activity for children was derived from adult values and modified 
based on the child’s body surface area as listed in tables published 
by the European Association of Nuclear Medicine (EANM).
Scintigraphic images were acquired at 40, 90 and 180 min-
utes after the administration of 99mTc-HMPAO labeled leukocytes us-
ing INFINIA gamma camera (GE Healthcare, Waukesha, WI, USA). 
The camera was fitted with a low-energy high-resolution parallel 
collimator. Early static images of the abdomen were acquired 
30–40 minutes after the administration of labeled leukocytes in 
an anterior and posterior projection, 500000 counts per image, and 
a matrix of 256 × 256 pixels. Single Photon Emission Computed 
Tomography (SPECT) of the abdomen was performed 90 min-
utes after the administration of labeled leukocytes. The following 
acquisition parameters were used: 60 images, 30–40 seconds per 
image, 128 × 128 pixel matrix. Whole body images were taken 
3 hours after the administration of labeled leukocytes in an anterior 
and posterior direction with a table movement speed of 5–10 cm 
per minute. Zoom was used as necessary.
The acquired images were evaluated both visually and 
semi-quantitatively using Cheow score [16] by an experienced 
physician blinded to the patients’ clinical data and outcome. Based 
on this score, the findings could be differentiated into 3 catego-
ries based on the degree and extent of pathologic activity (Tab. 1).
IBD was suspected when uptake (at least 1A by Cheow score) 
was present in the early abdominal images and became more 
pronounced in the late images.
To assess interobserver agreement, randomly selected 
42 scans were independently assessed by another nuclear medi-
cine physician.
Radiation dose was calculated using conversion coefficients of 
0.034 mSv/MBq for children up to 5 years and 0.011 mSv/MBq for older.
As the gold standard, we used the results of endoscopy with 
biopsy, other imaging modalities, and follow-up examinations evalu-
ated by an experienced pediatric gastroenterologist.
The statistical analysis was performed in Medcalc v.15 (Med-
calc software bvba, Ostend, Belgium). Sensitivity, specificity, and 
accuracy were calculated with their 95% confidence intervals (CI). 
Cheow score was compared by the Wilcoxon test. Interobserver 
agreement was expressed as kappa statistics. A p-value below 
0.05 was considered significant.
Results
Scintigraphy findings corresponded with the final diagnosis in 
78 (91%) of the 86 patients resulting in a sensitivity of 89% (95% CI 
Table 1. Scintigraphy results and the Cheow score — early and late phase
Patients with 
IBD
n = 28
Patients 
without IBD
n = 58
Cheow score
Scintigraphy phase Early Late Early Late
No activity 2 0 50 22
Degree of activity
1 — Barely detectable pathologic 
 activity in the abdominal cavity
2 0 3 13
2 — Between category 1 and 3 7 3 4 22
3 — Abnormal uptake with activity 
 at least as high as bone marrow
17 25 1 1
Extent
A — Single focus 2 0 1 9
B — Between category A and C 14 7 6 26
C — Diffuse inflammation 10 21 1 1
Evaluation
IBD by scintigraphy 25 5
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72 to 98%), specificity of 91% (95% CI 82 to 98%), and accuracy of 
91% (95% CI 83 to 96%). In 28 children (25 positives and 3 nega-
tives on scintigraphy), the diagnosis of IBD (26 Crohn’s disease, 1 
ulcerative colitis, 1 indeterminate) was established by endoscopy, 
histology, MR enterography, or fluoroscopy (Fig. 1 and Fig. 2). 
From 56 children with negative scintigraphy, three were ultimately 
diagnosed with IBD (all Crohn’s disease). Five positive scintigraphy 
findings were not confirmed by other methods or during follow-up.
The Cheow score was significantly higher both in the early and 
late phase in patients with IBD (p < 0.0001, Tab. 1). The interob-
server agreement was 0.82 (95% CI 0.75 to 0.88) and the radiation 
dose estimate was 4.2 ± 1.5 mSv. In 6 patients, scintigraphy found 
other locations of inflammation in the joints.
Discussion
In this study, we showed that scintigraphy with 99mTC-HMPAO 
labeled leukocytes in children with suspected IBD has high sensitiv-
ity for detecting the presence of inflammation in the gastrointestinal 
tract. The examination has an almost perfect interobserver agree-
ment and exposes other foci of inflammation in the body.
Nuclear medicine has proved usefulness in detecting inflam-
matory activity. Labeled leukocytes scintigraphy became an integral 
part of diagnostic algorithms. Leukocytes, monoclonal antibodies or 
their fragments labeled with 99mTc or 111In have been used. 111In is not 
suitable for imaging in children due to high radiation burden, and 
monoclonal antibodies are not routinely used in pediatrics as well. 
Therefore, scintigraphy with 99mTC-HMPAO labeled leukocytes be-
came the method of choice in children [16]. HMPAO is a complex 
molecule with lipid affinity, capable of penetrating blood cells. Once 
this molecule is internalized, it becomes hydrophile and remains in-
side the cell [17]. HMPAO shows a high affinity to granulocytes, 
where it remains in 86% [18]. Due to this complex action, it is used 
for the detection of inflammatory activity including IBD. Scintig-
raphy can also be used in patients with an already established 
diagnosis to evaluate treatment response and the degree of the 
inflammatory activity [19–21]. 
The presence of inflammatory activity detected using scin-
tigraphy in children with abdominal complaints warrants further 
investigation. These further indicated methods are usually more 
demanding requiring special preparation, anesthesia, or sedation. 
The cutting advantage of scintigraphy as a non-invasive screen-
ing test is its high sensitivity in identifying inflammation which 
is reported between 88% and 93% which is comparable with the 
results of our study [22, 23]. It is important to remember though, 
that this method has lower specificity ranging between 81% and 
91% [22, 23]. Another drawback is that scintigraphy does not show 
anatomic changes in the GI tract, mainly lumen narrowing, fistula 
formation and prestenotic dilatations. 
Figure 1. Crohn’s disease with ileocecal involvement. An early scintigram in a 12-year-old boy with a pathologic accumulation of labeled leukocytes 
in the right lower abdominal quadrant corresponding with the location of the terminal ileum, caecum, and the ascending colon (Cheow score 3C) 
confirms the presence of Crohn’s disease (A). A late scintigram with even more conspicuous pathologic accumulation (Cheow score 3C) in the same 
location (B). Small bowel follow through in the same boy shows cobblestoning and irregular luminal narrowing as typical features of Crohn’s disease 
in the terminal ileum, caecum and the ascending colon using MR enterography (C)
Figure 2. Crohn’s disease with ileocecal involvement. An early scintigram 
in an 11-year-old boy with a pathologic accumulation of labeled 
leukocytes in the right lower abdominal quadrant corresponding with the 
location of the terminal ileum, caecum, and the ascending colon (Cheow 
score 3C) confirms the presence of Crohn’s disease (A). A late scintigram 
with even more conspicuous pathologic accumulation (Cheow score 3C) 
in the same location (B). MR enterography shows marked thickening and 
mural enhancement of the ileum on a T1 (THRIVE) transversal section (C)
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Intestinal non-specific activity is usually present early in the 
course of the examination due to biliary excretion of the primary 
lipid soluble complex or its secondary metabolites. In adults, 
this activity is present within the first two hours since the applica-
tion of the labeled leukocytes [24]. In children, it can be visible 
within the first hour. This only emphasizes the importance of 
obtaining early images in children while this non-specific activity 
is not present.
During the last decade, new diagnostic methods for the detec-
tion and localization of inflammation including scintigraphy with 
99mTc-DMSA (Dimercaptosuccinic Acid) [25], 18F-FDG PET and 
PET/CT have been introduced into practice [13, 14, 26, 27]. Due to 
its high radiation burden, PET/CT is not regarded as the method of 
choice in diagnosing IBD in children and the evidence on the utility 
of 18F-FDG PET/CT in IBD is limited [28]. More recently, a retrospec-
tive study of Catalano et al [29] investigated the role of 18F-FDG 
PET/MRE in discriminating between inflammatory and fibrotic stric-
tures associated with CD. Another study documented that PET/MRE 
is more accurate than PET/CT in assessing extraintestinal disease 
in patients with CD [15, 30]. 
In comparison with another nuclear medicine imaging ex-
aminations by the radiation burden and price, scintigraphy with 
99mTc-HMPAO labeled leukocytes is the most efficient tool in the 
detection of IBD in children, providing information on the pres-
ence, the activity and the extent of active disease, particularly in 
the terminal ileum. According to our experience and in accordance 
with paper of Catalano et al. [14] this examination allows the evalu-
ation of areas of bowel that cannot be explored with colonoscopy 
and it could represent a non-invasive procedure not only for the 
diagnosis but also for follow-up and therapy monitoring in children. 
Compared to MRE, scintigraphy can find all locations affected by 
inflammation, including the stomach, perianal disease, reactive 
arthritis, and even enterocutaneous manifestations.
For ethical reasons, only a minority of children with negative 
findings on scintigraphy underwent endoscopy, MRE, fluoroscopy 
to confirm the absence of IBD, which is the most important limita-
tion of this study.
Conclusion
Scintigraphy with 99mTC-HMPAO labeled leukocytes in children 
with suspected IBD has high accuracy and offers a non-invasive 
option for detecting the presence of gastrointestinal inflammation. 
It also exposes other foci of inflammation in the body. Scintigraphy 
is a powerful non-invasive decision-making tool in the management 
of suspected IBD that may spare a greater proportion of children 
of more invasive and demanding examinations.
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